Liman Su

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma

Data on long-term outcomes of in vivo chimeric antigen receptor T cell (CAR‑T) therapy remain scarce. We previously reported preliminary safety and efficacy data of in vivo B-cell maturation antigen (BCMA) CAR‑T (ESO-T01), in four patients with relapsed/refractory multiple myelom...